388 related articles for article (PubMed ID: 31614491)
1. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
Fernando DH; Forbes JM; Angus PW; Herath CB
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491
[TBL] [Abstract][Full Text] [Related]
2. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
[TBL] [Abstract][Full Text] [Related]
3. The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review.
Sakasai-Sakai A; Takata T; Takino JI; Takeuchi M
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813302
[TBL] [Abstract][Full Text] [Related]
4. Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
Leung C; Herath CB; Jia Z; Goodwin M; Mak KY; Watt MJ; Forbes JM; Angus PW
J Hepatol; 2014 Apr; 60(4):832-8. PubMed ID: 24316518
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.
Takeuchi M; Takino J; Sakasai-Sakai A; Takata T; Ueda T; Tsutsumi M; Hyogo H; Yamagishi S
World J Hepatol; 2014 Dec; 6(12):880-93. PubMed ID: 25544875
[TBL] [Abstract][Full Text] [Related]
6. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr
Bijnen M; Beelen N; Wetzels S; Gaar JV; Vroomen M; Wijnands E; Scheijen JL; van de Waarenburg MPH; Gijbels MJ; Cleutjens JP; Biessen EAL; Stehouwer CDA; Schalkwijk CG; Wouters K
Sci Rep; 2018 Oct; 8(1):15256. PubMed ID: 30323247
[TBL] [Abstract][Full Text] [Related]
7. Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis.
Priken K; Tapia G; Cadagan C; Quezada N; Torres J; D'Espessailles A; Pettinelli P
Nutr Res; 2022 Aug; 104():71-81. PubMed ID: 35635899
[TBL] [Abstract][Full Text] [Related]
8. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
Ge X; Arriazu E; Magdaleno F; Antoine DJ; Dela Cruz R; Theise N; Nieto N
Hepatology; 2018 Dec; 68(6):2380-2404. PubMed ID: 29774570
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
10. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
[TBL] [Abstract][Full Text] [Related]
11. Identification of hub genes and key pathways of dietary advanced glycation end products‑induced non‑alcoholic fatty liver disease by bioinformatics analysis and animal experiments.
Wang J; Liu H; Xie G; Cai W; Xu J
Mol Med Rep; 2020 Feb; 21(2):685-694. PubMed ID: 31974594
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
Allam MM; El Gazzar WB
Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
14. Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products.
Santos JC; Valentim IB; de Araújo OR; Ataide Tda R; Goulart MO
Int J Mol Sci; 2013 Oct; 14(10):19846-66. PubMed ID: 24084729
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
[TBL] [Abstract][Full Text] [Related]
16. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
17. Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD.
Takeuchi M; Takino JI; Sakasai-Sakai A; Takata T; Tsutsumi M
Nutrients; 2017 Jun; 9(6):. PubMed ID: 28632197
[TBL] [Abstract][Full Text] [Related]
18. Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis.
Litwinowicz K; Waszczuk E; Gamian A
Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684371
[TBL] [Abstract][Full Text] [Related]
19. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
20. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling.
Tang Y; Chen A
Lab Invest; 2014 May; 94(5):503-16. PubMed ID: 24614199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
